Physician profile
Robert Shuler
NPI 1376644476
$3,339.48
in general payments reported to CMS, 2019-2025
15 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2021: $122 · 2022: $437 · 2023: $860 · 2024: $858 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $964.67 | 2022-2025 | Syfovre |
| Astellas Pharma US INC | $622.05 | 2023-2025 | Izervay |
| Genentech USA, INC. | $535.40 | 2021-2025 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $329.42 | 2019-2023 | Eylea |
| Regeneron Healthcare Solutions, INC. | $325.17 | 2021-2024 | Eylea Hd, Eylea |
| Genentech, INC. | $233.26 | 2023-2025 | Vabysmo, Susvimo |
| Eyepoint US, INC. | $82.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $77.70 | 2019 | |
| Alimera Sciences, INC. | $57.22 | 2024 | Iluvien, Yutiq |
| Biogen, INC. | $25.60 | 2022 | |
| Sight Sciences, INC. | $20.75 | 2024 | Omni Surgical System |
| Ani Pharmaceuticals, INC. | $20.36 | 2025 | Purified Cortrophin Gel |
| Notal Vision, INC. | $16.44 | 2019 | |
| Rxsight INC | $15.34 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Dutch Ophthalmic, USA | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shuler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.